Published in Nat Commun on February 13, 2017
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 49.00
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr (2011) 18.13
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet (2010) 13.86
Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med (2005) 9.47
How good are my data and what is the resolution? Acta Crystallogr D Biol Crystallogr (2013) 8.98
Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child (1986) 7.39
Naturally occurring antibodies devoid of light chains. Nature (1993) 7.35
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 3.90
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A (1997) 3.49
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol (2011) 2.53
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A (2006) 2.51
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology (2001) 2.38
Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol (1994) 2.29
A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature (1995) 2.29
Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A (2001) 2.04
The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol (2000) 2.04
Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med (2009) 2.03
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A (2012) 1.80
Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature (2013) 1.73
Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med (2011) 1.70
Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol (1998) 1.67
Condensed protocol for competent cell preparation and transformation of the methylotrophic yeast Pichia pastoris. Biotechniques (2005) 1.55
A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology (2012) 1.30
Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathog (2015) 1.23
Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem Biophys Res Commun (2001) 1.23
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol (2001) 1.22
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med (2015) 1.17
Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. J Gen Virol (2007) 1.15
The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol (2013) 1.01
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem (2015) 0.97
Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol (2013) 0.96
Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis (2011) 0.92
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J (2014) 0.88
Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol (2015) 0.88
Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution? J Virol (2015) 0.86
Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris. BMC Biotechnol (2009) 0.86
Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody. J Virol (2015) 0.85
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother (2015) 0.84
Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer. EBioMedicine (2016) 0.82
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther (2015) 0.82
Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacol Ther (2016) 0.81
Proof of principle for epitope-focused vaccine design. Nature (2014) 2.09
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature (2013) 2.08
Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun (2015) 1.02
The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals. Virus Res (2015) 0.80